Other developments in the HIV treatment landscape include the introduction of pre-exposure prophylaxis (PrEP) for the prevention of HIV acquisition. Uptake of PrEP has varied globally and there is a need to better understand how to remove barriers to access and increase PrEP use in those at risk of acquiring HIV.

The infectious disease portfolio also includes herpes simplex virus (HSV) for which there is currently no cure and treatment patterns vary greatly across patients according to level of symptomatic burden. Additionally, having HSV increases the risk of acquiring HIV, and therefore vaccines that prevent HSV are of particular interest as they have the potential to not only reduce transmission of HSV but also, indirectly, of HIV.

Furthermore, in the wake of the COVID-19 pandemic, the pressing need for effective prevention and treatment of respiratory infections has come to the forefront of the public, industry, and political consciousness. Resultantly, recent years have seen an unprecedented increase in the development of vaccines and treatments for a variety of common respiratory infectious diseases, including both COVID-19 and respiratory syncytial virus (RSV).

Building on our established respiratory and infectious disease portfolios, Adelphi Real World’s COVID and RSV DSPs seek to understand the acute and long-term symptomatic burden of COVID and RSV, in addition to defining the existing treatment and prevention landscape, attitudes towards vaccine uptake, and patient and caregiver burden associated with COVID and RSV in high-risk populations.

With renewed industry focus on the prevention and management of infectious diseases, and the associated drive for research and development of novel vaccines and treatments, it is imperative that these diseases, and their impact on patients, are holistically understood. As such, we are actively working to expand our infectious disease DSP portfolio, with a current focus on hepatitis, varicella, and Lyme disease.